Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AdvanDx
AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award
April 6th, 2008
AdvanDx announced it received Frost & Sullivan's 2008 Technology Innovation of the Year Award in the field of rapid in-vitro molecular diagnostic technology. The award recognizes how hospitals depend on AdvanDx's easy-to-use, molecular-based PNA FISH(TM) diagnostics to quickly identify bloodstream pathogens in hours instead of days. The rapid PNA FISH results enable laboratories to report critical information to physicians and pharmacists earlier to ensure optimal therapy and help reduce mortality rates for patients afflicted with bloodstream infections. 1,2 Frost & Sullivan's team of industry analysts conducted over 400 hours of analysis in the diagnostics market....
Source: Pharma Investments, Ventures & Law Weekly (2008-04-06)
|
